An antiplatelet monoclonal antibody, PMI-1, reacts with glycoproteins (GP) GPIIb, free GPIIb, and the GPIIb-HIa complex. This antibody binds to 40,900 sites per platelet, with a Kd = 0.95 gM, and its binding is inhibited by the presence of magnesium or calcium in the suspending medium (50% suppression at -0.5 mM divalent cation). Regulation of the PMI-1 epitope is independent of disassembly of the GPIIb-IIIa heterodimer, because it occurred at 220C and in response to mM magnesium as well as calcium. PMI-1 binding inversely correlated with fibrinogen binding. In addition, we identified a variant of Glanznn's thrombasthenia with near-normal platelet content of the GPIIbIIIa heterodimer as judged by crossed immunoelectrophoresis and surface labeling. Binding of PMI-1 to these patients' platelets was not dependent on reduction of the divalent cation concentration. These data suggest that the surface orientation of GPIIb is important in the capacity of platelets to bind fibrinogen.
linking of GPIIb-IIIa to derivatized Fg (1 1, 12) , and the demonstration ofassociation ofpartially purified GPIIb-IIIa with Fg in vitro (13) (14) (15) . Thus, GPIIb-IHa is clearly implicated in the ability of platelets to bind Fg and to aggregate.
GPIIb-IIIa exists as a calcium-dependent heterodimer in detergent solution (16, 17) ; Fujimura and Phillips (18) found that at >10 AM Ca", the complex was fully associated and that Mg++ was much less effective than Ca++ in this regard. The complex exists in isolated platelet membranes as judged by resistance to thrombin hydrolysis (18) and in intact resting platelets as judged by the binding of "complex-specific" monoclonal antibodies (6, 7, 9) where it accounts for most of the specific highaffinity surface Ca`binding sites (19) . Incubation of intact platelets at 37°C in the presence ofstrong Ca++-chelating agents ([free Ca++] <0.1 M) results in loss of binding of complexspecific antibodies (6, 7) apparently due to disassembly of the heterodimer (20, 21) ; loss ofaggregability (4, 20, 21) is associated with such treatment. Phillips and Baughan (22) also observed an absolute requirement for >1 MM Ca++ for Fg binding to isolated platelet membranes, and suggested that Ca`at these concentrations supported Fg binding by maintenance ofthe GPIIbIIIa heterodimer. These data, taken together, suggest that extracellular Ca`is required for maintenance of the GPIIb-IIIa heterodimer, which appears to be a prerequisite for Fg binding and aggregation. The critical Ca`concentrations are in the micromolar range; thus, heterodimer formation is unlikely to be regulated physiologically by this mechanism, because the normal extracellular free [Ca++] is maintained in the millimolar range.
In addition to the above-noted absolute Ca`requirement, several workers have observed that millimolar concentrations of Ca`or Mg++ are required for optimal aggregation and Fg binding to intact cells (3, 23) and membranes (22) , and Phillips and Baughan (22) have clearly distinguished this "nonselective" millimolar divalent cation requirement from the "selective" micromolar Ca" requirement. It is uncertain whether this second, possibly physiologically relevant, divalent cation requirement is mediated through GPIIb-IIIa, other sites on the platelet, or divalent cation-binding sites in the ligand (24). We now have identified regulation of the surface exposure of a region of GPIIb by Ca`or Mg`+ in the millimolar concentration range by use of a monoclonal antibody. This regulation appears to be functionally significant because it correlates with the capacity ofplatelets to bind Fg in the presence of various concentrations of divalent cations and in a novel variant of Glanzmann's thrombasthenia.
was produced as a consequence of immunization of Balb C mice with a platelet membrane preparation in Freund's adjuvant. The washed spleen cell suspension from these mice were fused with P3X63-AG8.653 myeloma cells at a 5:1 ratio and the fused cells were grown in hypoxanthineaminopterin-thymidine medium prior to being distributed in microtiter wells. A single colony of cells secreting an antibody that reacted with platelet membranes and inhibited platelet attachment to collagen (25) was selected and subcloned twice at limiting dilutions of 0.5 cell per well. This cell line, designated PMI-1, was injected into pristine primed mice (ascites fluid developed within 1 wk). Ascites from this subclone exhibited a single band of gamma mobility or cellulose acetate electrophoresis. IgG was prepared from ascitic fluid of by affinity chromatography on protein A-agarose (Pharmacia Fine Chemicals, Piscataway, NJ) in 0.1 ml of sodium phosphate buffer, pH 8, as previously described (25). This antibody was an IgG 1 kappa antibody by Ouchterlony immunodiffusion.
Binding assays andplatelet isolation. The platelets were isolated from acid citrate dextrose anticoagulated fresh human blood by differential centrifugation and gel filtration as previously described (2) . The platelets were ultimately suspended in a Tyrode's buffer containing 0.1% bovine serum albumin, pH 7.4. The ligands employed were '25I-monoclonal IgG or '25I-Fg labeled to specific activities of0.5-3 Asci/Ag by a chloramine-T procedure as described (2) (27) as published (28) . The labeled protein content of these surfaced labeled cells was analyzed by one-dimensional sodium dodecyl sulfkte-polyacrylamide gel electrophoresis (SDS-PAGE) by the technique of Laemmli with use of 10% mercaptoethanol to fully reduce surface glycoproteins. In nonreduced gels, 10 mM N-ethylmaleimide was added to prevent disulfide interchange (27) . Proteins were visualized by staining with Coomassie blue 250, gels were subsequently dried in vacuum and exposed for 3 h to 5 d at -70°C using Cronex Hiplus enhancing screen (DuPont Co., Wilmington, DE), and film was developed using a Kodak Xomat processor. Standards of reduced fibronectin (225,000 mol wt) and IgG H and L chains (55,000, 25,000 mol wt) were purified in our laboratory. Lactoperoxidase (78,000 mol wt) was provided by Calbiochem-Behring Corp. (La Jolla, CA) and lactic dehydrogenase (140,000 mol wt), phosphorylase B (94,000 mol wt), bovine serum albumin (68,000 mol wt), ovalbumin (43, 000 mol wt), and carbonic anhydrase (30,000 mol wt) were purchased from Pharmacia Fine Chemicals. To quantitate intensity of stained or autoradiographic bands, we utilized a soft laser densitometer no. SE504 (Biomed Instruments, Inc., Chicago, IL).
For two-dimensional gel electrophoresis we utilized a variant of the O'Farrell technique as previously published (28) . In this system, the proteins are reduced prior to isoelectric focussing. The pH gradients were determined by slicing the gel into 5 mM segments that were extracted in boiled deionized water; the pH of each fraction was measured on a pH meter. Coomassie blue staining and autoradiography were performed as described for Laemmli gels.
Two-dimensional peptide mapping of labeled peptides were performed exactly as described by Elder et al. (29) with the following modifications. A suspension containing a 1% Triton X-100 platelet lysate (109 cells/ml) and 5 mM EDTA 0.01 M Tris 0.15 M NCO, pH 7.4, was passed through a lentil lectin Sepharose (Pharmacia Fine Chemicals). Bound proteins were eluted in 0.1 M alpha methyl mannoside in the same buffer, and radioiodinated in detergent utilizing chloramine and 125I (2) . The radioiodinated material was then immunoprecipitated by use ofa goat polyclonal anti-GPIIb-IIIa and protein A containing staphylococci exactly as described previously (12) . The radiolabeled immunoprecipitate was eluted in sample buffer (28) and analyzed by SDS-PAGE under reducing conditions, and the major bands ofmol wt 123,000 (GPIIb alpha) and 105,000 (GPIII) were cut out, trypsin was digested, and the resultant peptides mapped by high-voltage electrophoresis followed by thin-layer chromatography exactly as described by Elder et al. (29) . Labeled spots were visualized by autoradiography.
For crossed immunoelectrophoresis, platelets were suspended to a concentration of 5 X 109/ml in 0.038 M Tris, 0.1 M glycine, pH 8.7. They were solubilized by agitation for 30 min at 4°C in the presence of 1% (vol/vol) Triton X-100, and insoluble material was pelleted by centrifugation at 20,000 g for I h at 4°C. These extracts were snap-frozen in liquid nitrogen, and stored at -70°C prior to being transported by air freight, without thawing, to the Blood Center of Southeastern Wisconsin, Milwaukee where analysis was performed. Crossed immunoelectrophoresis was performed as described (16) utilizing an intermediate gel. Radioimmunoassays for platelet factor 4, beta-thromboglobulin, and Fg have all been previously described (30) . These analyses were performed on 1% Triton lysates ofwashed platelets in the presence of5 mM EDTA.
Results PMI-I specificity. As reported previously, this monoclonal antibody blots to a single polypeptide with mobility identical to GPIIb-alpha in electrophoretic transfers ofnonreduced-reduced gels ofwhole platelet proteins (25). To further establish its specificity for this membrane protein, we analyzed the interaction of this antibody with two patients with known hereditary deficiency of GPIIb-IIIa. At the tested concentration, the patient's platelets bound 1 order of magnitude less PMI-1 than control platelets (Table I) . Thus, the species immunoblotted by this antibody is authentic GPIIb rather than a coelectrophoresed minor polypeptide. GPIIb known to contain the GPIIb-IIIa complex (16, 31) . When the cells were solubilized in the presence of 5 mM EDTA, band 16 was markedly reduced in height, and the antibody labeled a new more anodal arc which has previously been identified as containing GPIIb (16) (Fig. 1 ). Binding ofPMI-1 to platelets. We next evaluated the interaction of radiolabeled PMI-I with intact platelets. Surprisingly, very little antibody bound saturably to resting platelets in the presence of physiologic Mg"+ and Ca"+ concentrations (Fig. 2) . (1 MM) was incubated with 2 X 101 platelets at 370C for the indicated time, in the presence of 5 mM calcium (.) or 5 mM EDTA (o); bound was separated from free as described in Methods.
binding (Fig. 2) , which approached steady state by 30 min incubation. To further characterize the interaction ofthis antibody with platelets, we measured binding across a broad dose range. Binding was saturable (Fig. 3 ) and analysis by a nonlinear least squares curve-fitting program (26) was consistent with binding to a single class of sites (Kd = 0.95 MAM, 40,900 sites per cell, nonsaturable binding = 0.001, mean square error = 9.1). The number of sites estimated is in good agreement with measurements of the binding of GPIIb-specific antibodies to platelets (32) , suggesting the antibody does not recognize a subspecies of GPIIb.
Detailed analyses of divalent cation requirements for suppression of the PMI-1 epitope have been performed. When platelets were prepared in medium containing <0.1 MM Ca"+ (23) , PMI-I binding was comparable to that noted in the presence of 1 mM EDTA (Fig. 4) . Addition of either Mg"+ or Ca"+ as the chloride salt suppressed PMI-l binding; binding was 50% suppressed at -400 uM of either divalent cation and fully suppressed near physiologic concentrations (Fig. 4) . Thus, variations in local concentrations of Ca" and Mge' near the physiologic range may regulate expression of the PMI-I epitope.
To determine whether PMI-1 epitope exposure is reversible, we bound the antibody to platelets in the presence of EGTA for 30 min and then recalcified the platelet suspension. Addition of calcium eluted most (>90%) ofplatelet bound PMI-I by 60 min (Table II) . Thus, availability ofthe PMI-1 epitope on the platelet surface is reduced by Ca"+ even in the continuous presence of the antibody.
Relationship ofPMI-1 binding to binding ofFg and a cornplex-specific anti-GPIIb-IIIa. Fg binding to platelets is divalent ion dependent, and maintenance of the GPIIb-IIIa complex is calcium dependent. To explore potential relationships among these events, we compared the regulation of the binding of the complex-specific anti-GPIIb-IIIa, AP-2 (9), with PMI-I and Fg. At room temperature, the AP-2-binding site was maintained (Fig. 7) . Binding of Fg, fibronectin, and von Willebrand factor to thrombin-activated cells was also negligible (not shown). Thus, these individuals have a congenital, probably autosomal recessive platelet abnormality which is clin- ically and functionally typical of severe Glanzmann's thrombasthenia.
To further characterize the abnormality in this kindred, their platelet membrane proteins were analyzed by lactoperoxidasecatalyzed iodination followed by SDS-PAGE and autoradiography. No difference was apparent in the surface-labeling patterns (Fig. 8) , and densitometric quantitation of the GPIIIa/GPIIIb ratios revealed a value of 8.8±3.3 in normal (n = 5) and 7.3±1.7 (n = 4) in an affected member ofthis family. In contrast, similar analysis offour previously reported (33) thrombasthenia patients gave a mean ratio of 0.16±0.1 1. We considered the possibility that the patients lacked GPIIb-IIIa, but possessed another surfacelabelable species of similar size present in increased quantities or labeled with a higher specific activity as a consequence of their abnormality. To exclude this, their surface-labeled platelets were analyzed by O'Farrell two-dimensional gel electrophoresis. The major spots at apparent pI = 4.5 and Mr = 123,000 and 105,000 were not appreciably reduced relative to the normal (Fig. 9) . These spots have previously been identified as GPIIb alpha and GPIIIa in part by their deficiency in typical patients with thrombasthenia (28) . To establish definitively the identity of these species as GPIIb and lIla, two-dimensional tryptic peptide maps of the patients' proteins were compared with those of normal controls. Substantial differences between the maps of GPIIb and IIIa were apparent (Fig. 10 ) confirming previous work (34, 35) . Nevertheless, there was no consistent difference between the normals and the patients with respect to the maps for either protein. To determine whether there were any other abnormality in platelet protein content, the patients platelets were analyzed by crossed immunoelectrophoresis. In this analysis the absence of platelet Fg was apparent (Fig. 1 1) . Band 16 was present, but appeared ofreduced intensity. In addition, there was a suggestion of subtle anodic splitting of this arc (Fig. 1 1) . Free GPIIb and GPIIIa were not readily identified.
The data presented above indicate that these individuals possess GPIIb and IIIa, which exist, at least in part, in a complex, yet have severe Glanzmann's phenotype. To determine whether they manifested abnormal regulation of the PMI-l epitope, we studied the interaction of this antibody with their cells. In two of the affected patients, studied on four occasions, the binding of PMI-l to platelets was not influenced by the presence of divalent cations (Fig. 12) . Moreover, the affected individuals specifically bound >20,000 molecules per platelet confirming that they had at least 50% the normal content of GPIIb.
Discussion
The data reported here have defined a divalent cation dependent regulation of the surface exposure of the heavy chain of platelet membrane GPIIb. This regulation occurs in physiologic concentrations ofextracellular Ca" and Mg", and closely correlates with the capacity of platelets to bind Fg. It is presently not clear whether the divalent cations interact with the GP to render the PMI-1 epitope cryptic or whether the epitope is modulated through indirect effects of divalent cations at other sites on the platelet membrane. Nevertheless, abnormal regulation of the PMI-1 epitope appears to be a distinguishing feature of a novel variant of Glanzmann's thrombasthenia described herein. In addition, because the PMI-l antibody inhibits platelet-collagen Platelet aggregation assays were in 0.38% citrated platelet-rich plasma containing 2 X I08 platelets/ml, at 37'C, and with stirring at 1,100 rpm in a Sienco (Morrison, CO) dual-channel aggregometer. The left panel shows the response to 10 AM ADP, in which the normal platelet showed typical shape change and aggregation whereas the thrombasthenic (affected) show only shape change. The right panel shows similar aggregation responses to 100 ug/ml ristocetin.
adhesion in a Mg"+-dependent system, it may represent a prototype for a novel class of thrombus-directed antibodies. The PMI-l antibody unequivocally reacts with GPIIb alpha based upon Western blotting of two dimensional gels (25), crossed immunoelectrophoresis, and reduced reactivity with platelets deficient in GPIIb-IIIa. Moreover, McEver et al. (7, 32) have reported that Tab, an antibody directed against GPIIb, binds to 40,000 sites per platelet as did PMI-1; it therefore seems likely that the antibody does not recognize a subpopulation of the GP. Unlike Tab (7), PMI-l recognizes a divalent cationregulated epitope. Several laboratories have recently reported extracellular Ca"+ to <I gM, did not proceed rapidly at 220C, and could not be abrogated by Mg". In contrast, PMI-l is regulated at 220C as well as 370C and by Mg"+ as well as by Ca" in the millimolar range. Moreover, PMI-1 bound to the complex as well as the free GPIIb (Fig. 1) , and it could be regulated by Mg++ under conditions in which the binding of a "complexspecific" antibody did not vary.
One explanation for PMI-1 regulation is that the antibody recognizes a feature of the conformation of GPIIb. Brass and Shattil (19) have reported marked deficiency ofhigh-affinity (Kd =9 nM and 400 nM) selective Ca`binding sites in Glanzmann's thrombasthenia, suggesting these sites reside on the GPIIb-IIIa complex. In view of the different cation selectivity and concentration requirements, these high-affinity sites are unlikely to be those involved in PMI-l regulation. Nevertheless, the conformation of GPIIb could be regulated by lower-affinity divalent cation-binding sites on GPIIb, GPHIa, or indirectly via some other site on the platelet membrane. Alternatively, this antibody may recognize a site that is uncovered by-reorganization of the platelet surface which may occur as a consequence ofa reduction ofCa`+ and Mg`+ concentrations or of platelet interaction with certain surfaces.
Numerous investigators have identified a divalent cation requirement for platelet aggregation and stimulus induced binding of Fg to platelets (3, 23) . As noted in the introduction, the requirement for >10 IsM Ca" for maintenance of the GPIIb-IIIa complex (18, 20, 21) affords one potential explanation for divalent cation effects on Fg binding, but as also noted there is clear (3, 22, 23) evidence for regulation of Fg binding by millimolar concentrations of Mge' or Ca" independent ofthe state of the GPIIb-IIIa heterodimer. Because GPIIb-IIIa play a critical role in Fg receptor function, it seems likely that the changes in surface exposure ofGPIIb alpha is involved in this "nonselective" divalent cation regulation. Strong support for this concept comes from the striking correlation between regulation ofPMI-I epitope expression of Fg receptor function by divalent cations. In addition, divalent cations appear to regulate the epitope on the platelet rather than the antigen recognition function of the antibody, inasmuch as the antibody binds to the platelets of the variant of Glanzmann's thrombasthenia in the presence of Mg"+ and Ca"'. This Glanzmann's variant provides further compelling support for the physiologic significance of the PMI-l epitope, in that these platelets fail to express binding sites for three adhesive glycoproteins.
The most severely affected patients with Glanzmann's thrombasthenia are nearly completely deficient in GPIIb-IIIa, clot retraction, and Fg binding function and may have reduced intraplatelet Fg (36) . The present family has a hereditary, congenital bleeding disorder with absent clot retraction, and >95% deficits in platelet Fg content and binding function despite having at least 50% the normal content of GPIIb-IIIa, most of which is in the complex on crossed immunoelectrophoresis. The profound functional abnormalities in these patients clearly distinguish them from heterozygotes or "type II" (36, 37) Glanzmann's patients, who may manifest the presence ofreduced levels ofGPIIbIIIa. It is possible that the abnormality of platelet function in Figure 11 . Crossed immunoelectrophoresis of variant thrombasthenic platelets versus normal platelets, the anode is to the right. The extracts from normal and variant thrombasthenic platelets were analyzed by crossed immunoelectrophoresis as described in Fig. 1 . Coomassie bluestained plates are illustrated. In the right panel (normal control) note the prominent immunoprecipitin arc adjacent to the sample well which contains platelet Fg (arrowhead), and the major arc at the midpoint of the electrophoretigram (arrow) identified previously as band 16 which contains GP II/IIIa. In the left panel (patient) the former arc is absent. The band 16 arc (arrow) although of similar height, is of reduced staining intensity relative to the normal, and also shows subtle anodic splitting.
the present family is due to a qualitative abnormality in their GPIIb-IIIa. This seems particularly likely because they also manifest abnormal surface orientation of at least a portion of the GPIIb molecule. The lack of difference in tryptic peptide maps does not exclude qualitative difference in the GP in that only one protease was employed, only radiolabeled peptides were visualized, and minor sequence changes may not (30) , and cross-linking studies (42) has implicated GPIIb in platelet adhesion to collagen. 'The work of Shadle and Barondes (43) suggests that GPIIb is one of a multiplicity of platelet proteins that neutralize the ability of antiplatelet antibodies to inhibit Mg-dependent platelet adhesion to trimeric chick skin type I collagen. In addition, PMI-1, an antiGPIIb, blocked adhesion (25). Clearly, further study will be required to determine whether this antibody also blocks adhesion to other substrata. In addition, the capacity to block adhesion to collagen implies that this antibody bound to platelets under the conditions of the assay (2 mM Mg"+). If this epitope is exposed during membrane reorganization triggered by adhesion to a collagenous substrate, then this antibody may represent a prototype for novel thrombus-directed diagnostic and therapeutic reagents.
